[1] Chen WQ, Zheng RSh. Incidence,mortality and survival analysis of breast cancer in China[J]. Chinese Journal of Clinical Oncology, 2015,42(13):668-674.(in Chinese)
陈万青,郑荣寿.中国女性乳腺癌发病死亡和生存状况[J].中国肿瘤临床,2015,42(13):668-674.
[2] Bray F, Ferlay J, Soerjomataram Ⅰ, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018,68(6):394-424.
[3] Li RP, Zeng Zh, Zhao M, et al. Expression and clinical significance of Yes-related protein 1 in breast cancer[J]. Anatomy Research,2016,38(6):468-470, 474, 512. (in Chinese)
李瑞平,曾铮,赵敏, 等.Yes相关蛋白1在乳腺癌中的表达及临床意义[J].解剖学研究,2016,38(6):468-470, 474, 512.
[4] Huang YY, Bao Y. Experience breast cancer: from “disease“to “disability” of the female body[J]. Society, 2013,33(2):185-207. (in Chinese)
黄盈盈,鲍雨.经历乳腺癌:从“疾病”到“残缺”的女性身体[J].社会,2013,33(2):185-207.
[5] Zhang Q, Wu ZhSh, Zhang GH, et al. Expression of miR-145 in breast carcinoma and its significance[J]. Chinese Journal of Clinical and Experimental Pathology, 2009,25(1):9-12. (in Chinese)
张晴,吴正升,张瑰红,等.miR-145在乳腺癌中表达及意义[J].临床与实验病理学杂志,2009,25(1):9-12.
[6] Luo QC, Zhang H, Chen RSh, et al. Mechanism and function of microRNA mir-145 regulating Nanog in breast cancer cells[J]. Journal of Changsha University,2016,30(5):10-13, 16. (in Chinese)
骆启聪,张环,陈蓉珊,等.微小RNA mir-145在乳腺癌细胞中调控Nanog的机制与功能研究[J].长沙大学学报,2016,30(5):10-13, 16.
[7] Zhang BJ, Jin YX, Ma ZhL. The role of microRNA in tumors[J]. Chinese Journal of Nature,2014,36(5):364-372. (in Chinese)
张冰洁,金由辛,马中良.microRNA在肿瘤中的作用[J].自然杂志,2014,36(5):364-372.
[8] Ma ShY, Bai Y, Han N, et al. Recent research progress of biogenesis and functions of miRNA *[J]. Hereditas,2012,34(4):5-10. (in Chinese)
马圣运,白玉,韩凝,等.miRNA *生物合成及其功能研究的新发现[J].遗传,2012,34(4):5-10.
[9] Wang HCh, Zhang HJ, Hu ChJ. Roles of miRNA in breast cancer metastasis[J]. Chemistry of Life,2012,32(3):205-210. (in Chinese)
王焕春,张海静,胡成进.MiRNA在乳腺癌转移中的作用[J].生命的化学,2012,32(3):205-210.
[10]Chen B, Wei WD. Advances in the role of miRNAs in breast cancer drug resistance and related mechanisms[J]. Guangdong Medical Journal,2014,35(17):2791-2794. (in Chinese)
陈博,韦尉东.miRNA在乳腺癌耐药中的作用及其相关机制的研究进展[J].广东医学,2014,35(17):2791-2794.
[11]Zhang J. Functional study of miRNAs involved in breast cancer cell proliferation and metastasis[D]. Fudan University,2008. (in Chinese)
张进. 乳腺癌细胞增殖与转移相关miRNA的功能研究[D].复旦大学,2008.
[12]Zhao XA, Hu JH, Zhao XH. Effect of Hsa-miR-145 on invasion and migration potential in triple-negative breast cancer cell[J]. Chinese Journal of Clinicians(Electronic Edition),2012,6(15):4276-4279. (in Chinese)
赵晓艾,胡金华,赵新汉.Hsa-miR-145对人三阴性乳腺癌细胞侵袭和迁移的影响[J].中华临床医师杂志(电子版),2012,6(15):4276-4279.
[13]Ding J. Targeted regulation of BCL2L2 in breast cancer by miR-145[D]. East China Normal University,2016. (in Chinese)
丁健. miR-145在乳腺癌中对BCL2L2的靶向调控[D].华东师范大学,2016.
[14]Feng W, Wang C, Liang C, et al. The dysregulated expression of KCNQ1OT1 and its interaction with downstream factors miR-145/CCNE2 in breast cancer cells [J]. Cell Physiol Biochem, 2018,49(2):432-446.
[15]Quan Y, Huang X, Quan X. Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis [J]. Oncol Lett, 2018,16(5):6638-6642.
[16]Yamada Y, Koshizuka K, Hanazawa T, et al. Passenger strand of miR-145-3p acts as a tumor-suppressor by targeting MYO1B in head and neck squamous cell carcinoma [J]. Int J Oncol, 2018,52(1):166-178.
|